MS Australia has partnered with Australian research teams in five successful bids for government funding for research into the Epstein-Barr virus (EBV) in MS, totalling almost $10 million.
Scientists identify the first genetic marker for MS severity, opening the door to treatments for long-term disability.
Australian researchers have used blood immune cells to deliver a therapeutic protein to pre-clinical models of MS, which shows promise in the treatment of progressive MS.
CEO Rohan Greenland reflects on the remarkable progress made in MS therapies over the past three decades and emphasises MS Australia’s commitment to advocate and support the development of new and more effective treatments in the coming years.
Outstanding Australian MS Nurses, honored with MS Australia’s 50 Years President’s Medal, share their experiences, challenges, and hopes to inspire a new generation of MS Nurses
A recent study exploring the link between diet and MS disease progression showed that a pro-inflammatory diet increased the risk of relapses and larger lesions, indicating higher inflammatory activity.Â
MS Australia, together with Multiple Sclerosis organisations from Canada, Denmark, France, Germany, Italy, MS International Federation, Spain, U.K., and the U.S. have jointly declared their collective commitment to a global research strategy to cure MS.
MS Australia has today launched a new campaign at Parliament House on World MS Day (30 May) to raise awareness of the crucial role played by MS Nurses.
The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the listing of natalizumab (Tysabri®) pre-filled syringe for subcutaneous (under the skin) injection on the Pharmaceutical Benefit Scheme (PBS).
